Business Context and Reporting Period
This Form 8-K, dated February 9, 2026, reports the consummation of the spin-off of Becton, Dickinson and Company's (BD) Biosciences and Diagnostic Solutions business and its subsequent combination with Waters Corporation. The transaction closed on February 9, 2026, following a pro rata distribution of SpinCo common stock to BD shareholders as of the February 5, 2026 record date, and the immediate merger of SpinCo into Waters.
Key Financial Metrics and Capital Allocation
- Cash Proceeds: BD received a cash payment of $4 billion from SpinCo prior to the distribution and merger.
- Capital Allocation Plan: BD intends to utilize the $4 billion proceeds as follows:
- $2 billion for share repurchases via an accelerated share repurchase program.
- $2 billion for debt repayments.
- Equity Issuance: Waters issued 38,541,851 shares of its common stock to BD shareholders in exchange for their SpinCo shares.
- Exchange Ratio: Each share of SpinCo common stock was converted into approximately 0.1353 shares of Waters common stock.
Material Changes and Corporate Actions
- Business Separation: The Biosciences and Diagnostics Solutions Business has been legally separated from BD and is now a wholly owned subsidiary of Waters.
- Board Composition: Claire M. Fraser, Ph.D., resigned from the BD Board of Directors effective at closing to join the Waters Board. The BD Board size was reduced to twelve directors.
- Agreements Executed: BD, Waters, and SpinCo entered into definitive agreements covering Tax Matters, Employee Matters, Intellectual Property (including royalty-free licenses), and Transition Services (ranging from 3 to 24 months).
Outlook, Risks, and Management Commentary
Management expects the share repurchase and debt repayment initiatives to be executed in the near term, subject to market conditions. The filing notes that the Transition Services Agreement will facilitate the operational transition of the separated business, with BD providing HR, sales, marketing, finance, and IT services to the spun-off entity for up to 24 months. The filing does not provide specific forward-looking revenue or earnings guidance for the remaining BD business post-transaction.
Investor Verification Checklist
- Verify the execution timeline and market conditions affecting the $2 billion accelerated share repurchase program.
- Confirm the specific debt instruments targeted for the $2 billion repayment to assess impact on the capital structure.
- Review the Intellectual Property Matters Agreement to understand the scope of the royalty-free licenses granted to Waters and any retained rights for BD.
- Monitor the duration and cost implications of the Transition Services Agreement over the next 24 months.
- Assess the impact of the reduced board size and the departure of Dr. Fraser on corporate governance.